BioNTech Shareholders Unanimously Approve Board Overhaul and $1B Buyback as R&D Costs Surge Past €550 Million

BioNTech investors back strategic shift to cancer therapies as Q1 revenue plummets to €118M, R&D spending surges to €557M; stock repurchase program authorized.

The message from BioNTech’s annual shareholder meeting was unambiguous: investors are willing to stomach heavy losses today for a shot at oncology leadership tomorrow. With 92% of voting capital represented, every resolution passed, including a sweeping enlargement of the supervisory board and authorization for a fresh stock repurchase program. The moves come as the Mainz-based firm pivots hard away from its pandemic-era dependence on Covid vaccines and pours cash into a pipeline of experimental cancer therapies.

Board Expands to Eight as New Oncology Expertise Arrives

The supervisory board grows from six to eight members, adding two new faces with deep commercial and clinical backgrounds. Iris Löw-Friedrich and Susanne Schaffert join the ranks, bringing specific experience in oncology drug development and late-stage marketing. Helmut Jeggle, previously a board member, was elevated to chairman. Several existing mandates were also renewed, ensuring continuity while the company navigates its most consequential strategic shift since the Covid windfall.

Alongside the governance changes, shareholders greenlit a new authorized capital structure that could increase the share base by up to 50%. The move gives management flexibility to fund pipeline expansion without straining the balance sheet. That balance sheet remains robust: BioNTech sits on nearly $20 billion in cash and equivalents, providing ample runway for its research ambitions.

First-Quarter Results Reveal the Cost of Transformation

The financial toll of the oncology pivot was laid bare in first-quarter figures released on May 5. Revenue tumbled to €118.1 million, a fraction of the pandemic-era peaks, as vaccine sales continued to shrink. Vaccine-specific revenue stood at $138 million. The sharp drop drove a net loss of €531.9 million.

The primary culprit was research and development spending, which arrived at €557.0 million. In dollar terms, the company disclosed that outlays exceeded $650 million, reflecting heavy investment in immuno-oncology and antibody-drug conjugates. Among the programs consuming resources is pumitamig, a bispecific antibody that has become the centerpiece of BioNTech’s lung cancer strategy.

Management held firm on its full-year revenue guidance of €2.0 billion to €2.3 billion, a signal that a pipeline-driven recovery is still expected later in 2025 despite the current quarter’s weakness.

Buyback Mandate Secured, but Stock Remains Under Pressure

Alongside the governance updates, shareholders authorized a new share repurchase program of up to $1.0 billion over the next twelve months. The buyback targets American Depositary Shares and is designed primarily to offset dilution from equity-based compensation. It will be funded from existing cash reserves.

At the market close on Friday, BioNTech’s stock sat at €76.95, down 2.22% on the day and off 8.01% over the trailing 30 days. The shares trade 11.49% below their 200-day moving average and just 6.14% above the recent trough. The subdued price action reflects a market that wants proof of clinical progress before re-rating the stock.

Analysts remain cautiously constructive. The consensus is a "Moderate Buy" with a mean price target of roughly $130.60. That implies significant upside, but it hinges on data—not near-term revenue.

Pumitamig Data at ASCO Set to Test the Narrative

The next major catalyst arrives at the annual meeting of the American Society of Clinical Oncology in Chicago. The embargo on early abstracts lifts on May 21, giving investors a first look at the data BioNTech will present. The centerpiece is the ROSETTA-Lung-02 study, a Phase 2 trial testing pumitamig in combination with chemotherapy against the established standard of care, Merck’s Keytruda, in first-line non-small cell lung cancer.

On May 29, BioNTech will release the full Phase 2 results. A positive readout would provide the clinical validation the company desperately needs to justify its enormous R&D outlay. Pumitamig is one of several late-stage assets: BioNTech plans seven late-stage data readouts in oncology this year and aims to have 15 Phase 3 trials running by year-end.

The annual shareholder meeting has aligned governance squarely behind that pipeline push. Now the stock needs data to match the ambition.